June 12 – 17, 2022
With the goal of producing multivalent recombinant subunit filovirus and SARS-CoV-2 vaccines, we develop formulations using surface glycoproteins of Ebola, Marburg and Sudan viruses or the Spike protein of the SARS-CoV-2 virus. In determining the potency of our formulations in generating an immune response in mice and non-human primates (NHP), serum antibody titers are used. Instead of using conventional antigen-binding ELISA assays for each antigen, we conduct testing by a custom multiplex immunoassay. This method uses regionally different magnetic beads coupled to purified recombinant antigens which are incubated with serum dilutions to simultaneously determine the antibody titers to the different immunizing antigens. After application of a secondary, fluorescently labeled antibody, values are normally shown as median fluorescent intensity or MFI.
By converting the MFI to an actual concentration, samples from different studies can more easily be compared. For this, standard curves using purified antigen-specific immunoglobulin G (IgG) to the three filovirus GP’s or SARS-CoV2 spike protein are established with each assay. Standards were prepared passing high-titered mouse or NHP sera over a protein G column to isolate IgG, then purified further using affinity-chromatography columns with individual filovirus GP’s or SARS-CoV-2 spike protein to select for antigen-specificity. The standards are quantified and curves are generated which will be run with each set of serum samples.
Please click Download on the upper right corner to see the full abstract.
Teri Ann S. Wong, Albert To, and Axel Lehrer, "Development of a standardized multiplex Filovirus and SARS-CoV2 antibody immunoassay" in "Vaccine Technology VIII", Tarit Mukhopadhyay, Merck Research Laboratories, USA; Charles Lutsch, Sanofi Pasteur, France; Linda Hwee-Lin Lua, University of Queensland, Australia; Francesc Godia, Universitat Autònoma de Barcelona, Spain Eds, ECI Symposium Series, (2022). https://dc.engconfintl.org/vaccine_viii/57